

(19) World Intellectual Property Organization
International Bureau

P 12448EP

(43) International Publication Date
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number
WO 01/21658 A1(51) International Patent Classification: C07K 14/47,
C12N 5/10, 5/36, 15/17, 15/63, 15/64

(21) International Application Number: PCT/US00/26013

(22) International Filing Date:
22 September 2000 (22.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/155,709 24 September 1999 (24.09.1999) US(71) Applicant (for all designated States except US): HUMAN
GENOME SCIENCES, INC. [US/US]; 9410 Key West
Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): NI, Jian [CN/US];
5503 Manorfield Road, Rockville, MD 20853 (US).
BAKER, Kevin, P. [GB/US]; 14006 Indian Run Drive,
Darnestown, MD 20878 (US). BIRSE, Charles, E.
[GB/US]; 13822 Saddlevue Drive, North Potomac,
MD 20878 (US). ERNER, Reinhard [DE/US]; 9906
Shelburne Terrace, #316, Gaithersburg, MD 20878 (US).
FISCELLA, Michele [US/US]; 6808 Redwing Road,
Bethesda, MD 20817 (US). KOMATSOUIS, George,
A. [US/US]; 9518 Garwood Street, Silver Spring, MD
20901 (US). LAFLEUR, David, W. [US/US]; 3142
Quessada Street, N.W., Washington, DC 20015 (US).
MOORE, Paul, A. [GB/US]; 19005 Leatherback Drive,
Germantown, MD 20874 (US). OLSEN, Henrik, S.
[DK/US]; 182 Kendrick Place, #24, Gaithersburg, MD20878 (US). ROSEN, Craig, A. [US/AUS]; 22400 Rolling
Hill Road, Laytonsville, MD 20882 (US). RUBEN,
Steven, A. [US/AUS]; 18528 Heritage Hills Drive, Olney,
MD 20832 (US). SOPPET, Daniel, R. [US/US]; 15050
Stillfield Place, Centerville, MD 23020 (US). YOUNG,
Paul, E. [US/US]; 122 Beckwith Street, Gaithersburg, MD
20878 (US). WEI, Ping [CN/US]; 19100 Baltimore Road,
Brookville, MD 20833 (US). FLORENCE, Kimberly,
A. [US/US]; 12805 Atlantic Avenue, Rockville, MD
20851 (US).(74) Agents: HOOVER, Kentley, K. et al.; Human Genome
Sciences, Inc., 9410 Key West Avenue, Rockville, MD
20850 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: 32 HUMAN SECRETED PROTEINS

(57) Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding re-
gions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing
human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating dis-
eases, disorders, and/or conditions related to these novel human secreted proteins.

WO 01/21658 A1

the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating, preventing, and/or diagnosing neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

Moreover, Ocular diseases, disorders, and/or conditions associated with neovascularization which can be treated, prevented, and/or diagnosed with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalm.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalm.* 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating or preventing neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of